This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. (REGN) advanced 3.24% to $649.76 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&amp;P 500 Index rising 1.08% to 7,432.97 and the Dow Jones Industrial Average rising 1.31% to 50,009.35.
This was the stock's second consecutive day of gains.
Regeneron Pharmaceuticals Inc. closed 20.87% below its 52-week high of $821.11, which the company reached on January 9th.
The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Amgen Inc. (AMGN) rose 0.25% to $331.57, Moderna Inc. (MRNA) rose 5.25% to $48.12, and Gilead Sciences Inc. (GILD) rose 0.15% to $130.69.
Trading volume (1.1 M) eclipsed its 50-day average volume of 754,984.
Data source: Dow Jones Market Data, FactSet. Data compiled May 20, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-20-26 1646ET

REGN

SBIO

Regeneron Pharmaceuticals Inc. (REGN) shares rose 3.24% to $649.76 on a strong trading day, outperforming some competitors. The S&P 500 Index increased by 1.08%, while the Dow Jones Industrial Average rose by 1.31%. Despite the gains, REGN remains 20.87% below its 52-week high of $821.11. Trading volume reached 1.1 million, surpassing its 50-day average of 754,984.

MarketWatch Automated

Regeneron Pharma

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

SPDR S&P Biotech

VG Health

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

iShares Global Healthcare

S&P 500

Dow Jones Industrial Average

Amgen

Moderna

Gilead Sciences

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day